Список литературы

1. Stuart-Harris C.H. (chairman), Crofton J., Gilson J.C., Gough J. et al. Definition and Classification of Chronic Bronchitis. Lancet 10 April 1965; 775 - 779.

2. Braman S.S. Chronic Cough Due to Chronic Bronchitis. ACCP Evidence-Based Clinical Practice Guidelines. Chest 2006; 129: 104S - 115S.

3. Черняев А.Л. Патоморфология хронического обструктивного бронхита. РМЖ 1997: 17Т; 3 - 10.

4. Pallasaho P, Lundback B, Laspa SL. et al. Increasing prevalence of asthma but not of chronic bronchitis in Finland? Report from the FinEsS-Helsinki Study. Respir. Med. 1999; 93: 798 - 809.

5. Sobradillo V, Miravitlles M, Jimenez CA. et al. Epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): prevalence of chronic respiratory symptoms and airflow limitation. Arch Bronconeumol 1999; 35: 159 - 166. [PubMed] [Google Scholar].

6. Cerveri I, Accordini S, Verlato G. et al. European Community Respiratory Health Survey (ECRHS) Study Group. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J 2001; 18: 85 - 92. [PubMed] [Google Scholar].

7. Janson C, Chinn S, Jarvis D, Burney P. Determinants of cough in young adults participating in the European Community Respiratory Health Survey. Eur Respir J 2001; 18: 647 - 654. [PubMed] [Google Scholar].

8. Huchon GJ, Vergnenegre A, Neukirch F. et al. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur Respir J 2002; 20: 806 - 812. [PubMed] [Google Scholar].

9. Miravitlles M, de la Roza C, Morera J. et al. Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. Respir Med 2006; 100: 1973 - 1980. [PubMed] [Google Scholar].

10. Pelkonen M, Notkola IL, Nissinen A. et al. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006; 130: 1129 - 1137. [PubMed] [Google Scholar].

11. de Marco R, Accordini S, Cerveri I. et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007; 175: 32 - 39. [PubMed] [Google Scholar].

12. Miravitlles M, Soriano JB, Garcia-Rio F. et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009; 64: 863 - 868. [PubMed] [Google Scholar].

13. Martinez C, Chen Y, Kazerooni E. et al. Non-obstructive chronic bronchitis in the COPDGene cohort [abstract]. Am J Respir Crit Care Med 2012; 185: A6622. [Google Scholar].

14. Косарев В.В., Бабанов С.А. Социальные аспекты хронического бронхита по данным эпидемиологического исследования. Экология человека. 2005. - N 12. - С. 46 - 49.

15. Международная классификация болезней 10-го пересмотра. https://mkb-10.com/.

16. Braman S.S. Chronic cough due to chronic bronchitis. ACCP evidence-based clinical practice guidelines. Chest 2006; 129 (Suppl 1): 104S - 115S.

17. Celli B, MacNee W, ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932 - 946.

18. Синопальников А.И., Клячкина И.Л. Кашель. Карманные рекомендации. М.: ООО "Группа РЕМЕДИУМ", 2013.

19. Irwin R.S., French C.I., Chang A.B. et. al. Classification of Cough as a Symptom in Adults and Management Algorithms. CHEST Guideline and Expert Panel Report 2018; 153 (1): 196 - 209.

20. Шепеленко А.Ф. Хронический бронхит. Трудный пациент. 2009; 7 (3): 33 - 38.

21. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 Report). Available at: https://goldcopd.org

22. Smith J.A., Woodcock A. Chronic cough. N Engl J Med 2016; 375: 1544 - 1551.

23. Terasaki G., Paauw D.S. Evaluation and treatment of chronic cough. Med. Clin. N. Am. 2014; 98: 91 - 403.

24. Achilleos A. Evidence-based evaluation and management of chronic cough. Med. Clin. N. Am. 2016; 100: 1033 - 1045.

25. Dicpinigaitis P.V. & Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129 (Suppl 1): 169S - 173S.

26. Pratter M.R. Overview of common causes of chronic cough. ACCP evidence-based clinical practice guidelines. Chest 2006; 129 (Suppl 1): 59S - 62S.

27. Lai K., Shen H., Zhou X. et al. Clinical practice guidelines for diagnosis and management of cough: Chinese Thoracic Society (CTS) Asthma Consortium. J Thorac Dis 2018; 10: 6314 - 6351.

28. Irwin R.S. Chronic Cough Due to Gastroesophageal Reflux Disease ACCP evidence-based clinical practice guidelines Chest 2006; 129 (Suppl 1): 59S - 62S).

29. Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease//Ann Intern Med 1987; 106 (2): 196 - 204.

30. Woodhead M., Blasi F., Ewig S., et al. New guidelines for the management of adult lover respiratory tract infections. Clin Microbiol Infect 2011; 17 (6): 1 - 59.

31. Weis N, Almdal T C-reactive protein - can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2006; 17: 88 - 91.

32. Dev D, Sankaran EWR, Cunnife J et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir. Med. 1998; 92: 664 - 667.

33. Wynder E., Kaufman P., Lerrer R., et al. A short term follow up study on ex-cigarette smokers: with special emphasis on persistent cough and weight gain. Am Rev Respir Dis 1967; 96: 645 - 655.

34. Chandler M.A., Rennard S.I.: Smoking cessation. Chest 2010; 137: 428 - 435.

35. Hukkinen M, Korhonen T, Broms U, et al. Long-Term Smoking Behavior Patterns Predicting Self-Reported Chronic Bronchitis. J COPD 2009; 6: 242 - 249.

36. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., Smith S.S., Muramoto M.L., Daughton D.M., Doan K., Fiore M.C., Baker T.B.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685 - 691.

37. Faessel H., Ravva P., Williams K.: Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther 2009; 31: 177 - 189.

38. Willemse BWM, Postma DS, Timens W, ten Hacken NHT. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23: 464 - 476.

39. Anthonisen N.R., Connett J.E., Kiley J.P., Altose M.D., Bailey W.C., Buist A.S., Conway W.A. Jr., Enright P.L., Kanner R.E., O'Hara P.: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV 1. The Lung Health Study. JAMA 1994; 272: 1497 - 1505.

40. Kardos P., Berck H., Fuchs K.H., et al. Guidelines of the German respiratory society for diagnosis and treatment of adults suffering from acute or chronic cough. Pneumologie. 2010; 64: 701 - 711;

41. Kardos P., Dinh Q.T., Fuchs K.H. et al. Guidelines of the German Respiratory Society for Diagnosis and Treatment of Adults Suffering from Acute, Subacute and Chronic Cough Pneumologie 2019; 73: 143 - 180.

42. Poole P., Black P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev 2010; 2: CD001287.

43. Sevelius H., McCoy J.F., Colmore J.P. Dose response to codeine in patients with chronic cough. Clin Pharmacol Ther 1971; 12: 449 - 455.

44. Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev 2019 May 20; 5 (5): CD001287.

45. Aylward M., Maddock J., Davies D.E. et al. Dextromethorphan and codeine: comparison of plasma kinetics and antitussive effects. Eur J Respir Dis 1984; 65: 283 - 291.

46. Melloni B., Germouty J. The influence of a new beta agonist formoterol on mucociliary function. Rev Mal Respir 1992; 9: 503 - 507.

47. Ghafouri R., Patil K., Kass I. Sputum changes associated with the use of ipratropium bromide. Chest 1984; 86: 387 - 393.

48. Casaburi R., Mahler D., Jones P., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217 - 224.

49. Ram F., Jones P., Castro A. et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (database online). Issue 4, 2004.

50. Lai K, Shen H, Zhou X, et al. Clinical Practice Guidelines for Diagnosis and Management of Cough-Chinese Thoracic Society (CTS) Asthma Consortium. J Thorac Dis 2018; 10: 6314 - 6351.

51. Staykova T., Black P., Chacko E. et al. Prophylactic antibiotic therapy for bronchitis. Cochrane Database Syst. Rev. (database online). Issue 4, 2004.

52. Adams S, Luther M. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of chronic obstructive pulmonary disease Chest 2000; 117: 1345 - 1352.

53. Dimopoulos G., Siempos I.I., Korbila I.P. et al. Comparison of first line with secondline antibiotics for acute exacerbations of chronic bronchitis: a meta-analysis of randomized controlled trials. Chest 2007; 132: 447 - 455.

54. M., et al. Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults. Multidiscip Respir Med. 2018 Nov 2; 13: 40.

55. Miravitlles M, Espinosa C, Fernandez-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116 (1): 40 - 46.

56. Синопальников А.И., Зайцев А.А. Антибактериальная терапия при обострении хронической обструктивной болезни легких: фокус на длительность "безынфекционного" периода. Consilium Medicum. - 2012. - Т. 14. - N 3. - С. 74 - 78.

57. Siempos II, Dimopoulos G, Korbila IP, Manta K, Falagas ME. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J. 2007 Jun; 29(6): 1127 - 37. doi: 10.1183/09031936.00147806. Epub 2007 Feb 14. PMID: 17301097.

58. Falagas M., Avgeri S., Matthaiou D., Dimopoulos G., Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother. 2008; 62 (3): 442 - 450.

59. Lorenz J., Steinfeld P., Drath L., Keienburg T., et al. Efficacy and Tolerability of 5- vs 10-Day Cefixime Therapy in Acute Exacerbations of Chronic Bronchitis. Clin Drug Investig. 1998; 15 (1): 13 - 20.

60. Синопальников А.И., Зайцев А.А. Комплаентность пациентов с инфекциями дыхательных путей. Клиническая микробиология и антимикробная химиотерапия. - 2008; 1: 50 - 59.

61. Chodosh S., DeAbate C., Haverstock D., et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med 2000; 94: 18 - 27.

62. Masterton R., Burley C. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis Int J Antimicrob Agents 2001; 18: 503 - 512.

63. Higgings BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991; 4: 415 - 420.

64. Chen M, Chen P, Zhong N, et al. The Chinese national guidelines on diagnosis and management of cough (December 2010). Chinese Medical Journal 2011; 124 (20): 3207 - 3219.

65. Rubin B.K.. Mucolytics, expectorants, and mucokinetic medications. Respir Care. 2007; 52: 859 - 865.

66. Avdeev S.N., Vizel A. A., Abrosimo V.N., Zaicev A.A. et al. Management of Cough in Patients with Chronic Obstructive Pulmonary Disease: Results of the Multicenter Randomized Placebo-Controlled Clinical Trial. International Journal of Chronic Obstructive Pulmonary Disease 2021: 16 1243 - 1253.

67. Зайцев А.А., Оковитый С.В. Кашель: дифференциальный диагноз и рациональная фармакотерапия. Терапевтический архив. 2014; Т. 86, N 12: 85 - 91.

68. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173: 1390 - 413.

69. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007; 131: 4S - 42S.

70. Mahler DA. Pulmonary rehabilitation. Chest 1998; 113: 263S - 8S.

71. Heffner JE, Fahy B, Hilling L, Barbieri C: Outcomes of advance directive education of pulmonary rehabilitation patients. Am J Respir Crit Care Med 1997; 155: 1055 - 1059.

72. Stewart MA: Effective ph Heffner JE, Fahy B, Hilling L, Barbieri C: Outcomes of advance directive education of pulmonary rehabilitation patients. Am J Respir Crit Care Med 1997; 155: 1055 - 1059.

73. Гриппозные вакцины: документ по позиции ВОЗ. Еженедельный эпидемиологический бюллетень. 2012, 87 (47): 461 - 476.

74. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2014 - 2015. Morb. Mortal. Wkly Rep. 2014; 63 (32); 691 - 697.

75. Moberley S., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 2013; 1: CD000422.

76. Приказ Министерства здравоохранения Российской Федерации от 15 ноября 2012 г. N 916н "Об утверждении Порядка оказания медицинской помощи населению по профилю "пульмонология"/https://rg.ru/2013/04/11/legkie-dok.html

77. Amalakanti S., Pentakota M. R. Pulse oximetry overestimates oxygen saturation in COPD//Respiratory care. - 2016. - Т. 61. - N. 4. - С. 423 - 427.

78. M. O. et al. Radiological diagnosis in lung disease: factoring treatment options into the choice of diagnostic modality//Deutsches International. - 2014. - Т. 111. - N. 11. - С. 181.

79. Agarwal R. L. et al. Diagnostic values of electrocardiogram in chronic obstructive pulmonary disease (COPD)//Lung India: Official Organ of Indian Chest Society. - 2008. - Т. 25. - N. 2. - С. 78.

80. Feeney A. S., Fendrick A. M., Quintiliani R. Acute exacerbation of chronic bronchitis: a primary care consensus guideline//The American journal of managed care. - 2004. - Т. 10. - С. 689 - 696.

81. Pelkonen M. Smoking: relationship to chronic bronchitis, chronic obstructive pulmonary disease and mortality//Current opinion in pulmonary medicine. - 2008. - Т. 14. - N. 2. - С. 105 - 109.

82. Cazzola M., Page C. Long-acting bronchodilators in COPD: where are we now and where are we going?//Breathe. - 2014. - Т. 10. - N. 2. - С. 110 - 120.

83. El Moussaoui R. et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies//Thorax. - 2008. - Т. 63. - N. 5. - С. 415 - 422.

84. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001 Apr; 163 (5): 1256 - 76. doi: 10.1164/ajrccm.163.5.2101039. PMID: 11316667.

85. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999 Jun 24; 340(25): 1941 - 7. doi: 10.1056/NEJM199906243402502. PMID: 10379017.

86. Walters J. A. E. et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease//Cochrane Database of Systematic Reviews. - 2014. - N. 9.

87. Berton DC, Reis M, Siqueira AC, et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med. 2010; 104(9): 1288 - 1296. doi: 10.1016/j.rmed.2010.05.017.

88. Tashkin DP, Donohue JF, Mahler DA, et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med. 2009; 103(4): 516 - 524. doi: 10.1016/j.rmed.2008.12.014.

89. D"Urzo A, Rennard S, Kerwin E, et al. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respir Med. 2017; 125: 39 - 48. doi: 10.1016/j.rmed.2017.02.008.

90. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013; 309(21): 2223 - 2231. doi: 10.1001/jama.2013.5023.